Hepatitis C News and Research

Latest Hepatitis C News and Research

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

10 Nov 2010

Miriam Hospital receives NIH grants to improve HIV treatment for jail inmates

The Miriam Hospital received three of the 12 newly awarded grants from the National Institutes of Health (NIH) aimed at improving HIV prevention and treatment of prison and jail inmates.

10 Nov 2010

Forceps delivery can pose risk to mother and child

Forceps might be a better instrument than a vacuum cup for assisting a successful birth, but new mothers might experience more trauma and complications after a forceps delivery, according to a new review of studies.

10 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Researchers examine burden of HIV and sexually transmitted diseases in China

A new study by researchers at the Johns Hopkins Bloomberg School of Public Health examines the burden of HIV and sexually transmitted disease among male clients of the commercial sex industry in China's Sichuan province

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Vaccinations do not increase risk of RA

Common adult vaccinations are not associated with an increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.

8 Nov 2010

AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

AiCuris announced today the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7th – 9th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.

7 Nov 2010

Experts develop tools to educate people about health risks associated with global travel

More than 30 million people in the United States travel to resource-limited areas of the world each year. This global mobility may contribute to the spread of infectious diseases such as influenza, measles, and meningitis and may also put individual travelers at risk for malaria, typhoid, dengue fever and hepatitis.

4 Nov 2010

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Revolutions Medical announces completion of designs for 5ml and 10ml fixed needle RevVac Safety Syringes

Revolutions Medical Corporation announced today that due to the launch of its 3ml RevVac Safety SyringeTM during the Medica show in Dusseldorf, Germany and the enormous interest that the launch has received from healthcare professionals and corporations in Europe, the company will host an additional reception in London on Saturday, November 20th from 7:30 PM - 9:30 PM at the Landmark Hotel, Tower Suite.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.

3 Nov 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Miriam Hospital receives NIH grants to improve HIV treatment for jail inmates

Forceps delivery can pose risk to mother and child

Research report on current and evolving technologies in drug delivery

Researchers examine burden of HIV and sexually transmitted diseases in China

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Vaccinations do not increase risk of RA

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

Experts develop tools to educate people about health risks associated with global travel

Cocrystal receives $733,438 in grants from QTDP program

Regulus receives $488,989 grant under QTDP program

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Revolutions Medical announces completion of designs for 5ml and 10ml fixed needle RevVac Safety Syringes

Top 10 Medical Innovations for 2011

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

Mastering RNA extraction for plant and fungal research – eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in